Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization

Eye (Basingstoke)

Volumn 26, Issue 7, 2012, Pages 976-982

  Introini, U ^a   Casalino, G ^a   Querques, G ^a   Gimeno, A T ^a   Scotti, F ^a   Bandello, F ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

anti VEGF; choroidal neovascularization; pathologic myopia; spectral domain OCT

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MYOPIA; RETINA; RETINA FLUORESCEIN ANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION;

EID: 84863879968     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.75     Document Type: Article

References (23)

1. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90(8): 923-926. (Pubitemid 13004305)
2. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91(12): 1573-1581. (Pubitemid 15197032)
3. Yoshida T,Ohno-MatsuiK, YasuzumiK, Kojima A, ShimadaN, Futagami S et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110(7): 1297-1305.
4. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3.Ophthalmology 2003; 110(4): 667-673. (Pubitemid 36520061)
5. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29(8): 1062-1066.
6. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118(4): 663-671.
7. Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 2011; 31(8): 1609-1619.
8. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
10. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444. (Pubitemid 44511558)
11. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
12. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114(12): 2190-2196.
13. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247(3): 311-318.
14. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30(3): 407-412.
15. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009; 23(6): 1275-1280; quiz 1281.
16. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147(1): 84-93.e1.
17. Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010; 30(3): 399-406.
18. Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia vs age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 2008; 92(8): 1081-1085.
19. Witkin AJ, Ko TH, Fujimoto JG, Chan A, Drexler W, Schuman JS et al. Ultra-high resolution optical coherence tomography assessment of photoreceptors in retinitis pigmentosa and related diseases. Am J Ophthalmol 2006; 142(6): 945-952.
20. Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005; 139(1): 87-99. (Pubitemid 40094844)
21. Villate N, Lee JE, Venkatraman A, Smiddy WE. Photoreceptor layer features in eyes with closed macular holes: optical coherence tomography findings and correlation with visual outcomes. Am J Ophthalmol 2005; 139(2): 280-289. (Pubitemid 40288273)
22. Inoue M, Watanabe Y, Arakawa A, Sato S, Kobayashi S, Kadonosono K. Spectral-domain optical coherence tomography images of inner/outer segment junctions and macular hole surgery outcomes. Graefes Arch Clin Exp Ophthalmol 2009; 247(3): 325-330.
23. Sayanagi K, Sharma S, Kaiser PK. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol 2009; 93(5): 622-626.